A phase III trial of <i>nab</i>-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on <i>BRAF</i> status.
Evan M. Hersh, Axel Hauschild(University Hospital Schleswig-Holstein), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Richard Kefford(Broad Institute), Markus F. Renschler(Princess Margaret Cancer Centre), Carmen Loquai(Johannes Gutenberg University Mainz), Mingyu Li, Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ileana Elias, Michael P. Brown(South Australia Pathology)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k